Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
17
APVO Quote, Financials, Valuation and Earnings
Last price:
$4.99
Seasonality move
:
-22.85%
Day range:
$4.53 - $4.93
52-week range:
$4.30 - $658.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.10x
Volume:
70.8K
Avg. volume:
356.2K
1-year change:
-99.12%
Market cap:
$3.2M
Revenue:
--
EPS (TTM):
-$1,596.48
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Aptevo Therapeutics has 8798.31% upside to fair value with a price target of $21.00 per share.
APVO vs. S&P 500
-
Over the past 5 trading days, Aptevo Therapeutics has underperformed the S&P 500 by -22.78% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aptevo Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aptevo Therapeutics has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Aptevo Therapeutics reported revenues of --.
Earnings Growth
-
Aptevo Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aptevo Therapeutics reported earnings per share of -$87.80.
Enterprise value:
1M
EV / Invested capital:
--
Price / LTM sales:
0.02x
EV / EBIT:
--
EV / Revenue:
0.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$30.8M | -$28.1M | -$24.1M | -$7M | -$6.5M | |
| EBITDA | -$29.9M | -$27.6M | -$23.8M | -$6.9M | -$6.4M | |
| Diluted EPS | $119,597.83 | -$66,070.35 | -$1,596.48 | -$7,509.89 | -$87.80 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.9M | $41.7M | $28.5M | $12.1M | $3.6M | |
| Total Assets | $68.8M | $45.2M | $35M | $17.6M | $8.3M | |
| Current Liabilities | $29.3M | $23.9M | $5.8M | $6.3M | $5.4M | |
| Total Liabilities | $58.2M | $51.1M | $11.7M | $11.5M | $9.8M | |
| Total Equity | $10.5M | -$5.9M | $23.3M | $6.1M | -$1.5M | |
| Total Debt | $14.8M | $4.8M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.3M | -$22.9M | -$23.7M | -$6.7M | -$6.6M | |
| Cash From Investing | -$29K | -- | -- | -- | -- | |
| Cash From Financing | $447K | $7.9M | $15.6M | -$3K | -- | |
| Free Cash Flow | -$11.3M | -$22.9M | -$23.7M | -$6.7M | -$6.6M | |
APVO
Sector
Market Cap
$3.2M
$33.4M
Price % of 52-Week High
0.72%
45.16%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-99.12%
-40%
Beta (5-Year)
5.759
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.53
200-day SMA
Sell
Level
$114.45
Bollinger Bands (100)
Sell
Level
13.25 - 78.35
Chaikin Money Flow
Sell
Level
-9M
20-day SMA
Sell
Level
$6.62
Relative Strength Index (RSI14)
Sell
Level
25.70
ADX Line
Buy
Level
12.2
Williams %R
Buy
Level
-95.8142
50-day SMA
Sell
Level
$16.60
MACD (12, 26)
Sell
Level
-3.59
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
7.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Stock Forecast FAQ
In the current month, APVO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The APVO average analyst price target in the past 3 months is $21.00.
-
Where Will Aptevo Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aptevo Therapeutics share price will rise to $21.00 per share over the next 12 months.
-
What Do Analysts Say About Aptevo Therapeutics?
Analysts are divided on their view about Aptevo Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aptevo Therapeutics is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Aptevo Therapeutics's Price Target?
The price target for Aptevo Therapeutics over the next 1-year time period is forecast to be $21.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is APVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aptevo Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of APVO?
You can purchase shares of Aptevo Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aptevo Therapeutics shares.
-
What Is The Aptevo Therapeutics Share Price Today?
Aptevo Therapeutics was last trading at $4.99 per share. This represents the most recent stock quote for Aptevo Therapeutics. Yesterday, Aptevo Therapeutics closed at $4.72 per share.
-
How To Buy Aptevo Therapeutics Stock Online?
In order to purchase Aptevo Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is up 2.1% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 12.88% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is down 0.66% over the past day.
